We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Natural Antibodies Can Prevent Adverse Immune Reactions

By LabMedica International staff writers
Posted on 11 Mar 2019
Natural antibodies, in particular IgG, have been shown to be a critical factor that determines the efficiency of complement activation in different subjects and by different nanomaterials.

Deposition of complement factors (opsonization) on nanoparticles may promote clearance from the blood by macrophages and trigger pro-inflammatory responses, but the mechanisms regulating the efficiency of complement activation are poorly understood.

Opsonization is the molecular mechanism whereby molecules, microbes, or apoptotic cells are chemically modified to have stronger interactions with cell surface receptors on phagocytes and natural killer (NK cells). More...
With the antigen coated in opsonins, binding to immune cells is greatly enhanced. Opsonization also mediates phagocytosis via signal cascades from cell surface receptors. Opsonins aid the immune system in a number of ways: in a healthy individual, they mark dead and dying self-cells for clearance by macrophages and neutrophils, activate complement proteins, and target cells for destruction through the action of NK cells.

Investigators at the University of Colorado (Aurora, CO, USA) previously found that opsonization of superparamagnetic iron oxide (SPIO) nanoworms with the third complement protein (C3) was dependent on the biomolecule corona of the nanoparticles. C3 is a molecule that plays a central role in the activation of the complement system, and its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection.

In a paper published in the January 14, 2019, online edition of the journal Nature Nanotechnology, the investigators reported that binding of only a few immunoglobulin molecules, and specifically IgG, determined the efficiency of C3 deposition on nanomaterials introduced into the plasma and sera of healthy donors and in plasma of cancer patients, regardless of the complement activation pathway. Moreover, the presence of the biomolecule corona enhanced IgG binding to all tested nanomaterials.

“In all of the nanoparticles that we tested, complement activation was dependent on the binding of certain of these natural antibodies to nanoparticles,” said senior author Dr. Dmitri Simberg, associate professor of pharmaceutical sciences at the University of Colorado. “Interestingly, the antibodies bind to the proteins in the corona, rather than to the pristine nanoparticle surface itself. If a person has a high level of antibodies that can recognize a particular type of nanoparticle, this person will have high complement activation. The study gave us an exciting new angle on how the system recognizes nanomaterials. This knowledge step is important for designing a better coating so the particles can be more biocompatible and safer. I am a really big fan and proponent of mechanistic studies in the nanodrug delivery field that can guide us to better designs.”

Related Links:
University of Colorado


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.